Reading the tape
NASDAQ: RXST
RxSight, Inc.
Healthcare · Medical - Devices
Market Cap
$304.55M
52w High
$16.74
52w Low
$5.90
P/E
-7.80
Volume
631.06K
Outstanding Shares
41.27M
Price vs Fundamentals
Why The Stock Is Moving
Mixed / unclearLow confidence
Note: The most recent financial data is over 3 months old. Metrics shown may not reflect the latest reporting period.
1Y Price: -49.59%Revenue (TTM): -10.36%FCF (TTM): 100%P/S: 0th pct
What changed
The stock fell 49.59% over the last year. Revenue declined 10.36% over the trailing twelve months. Operating margin moved from -24.57% to -35.84%. Free cash flow grew 100% over the trailing twelve months.
What the market seems to be pricing
The stock has moved lower against modestly weakening underlying metrics. The operating data does not yet tell a clear story — the move may reflect sentiment, sector rotation, or macro factors rather than company-specific earnings power.
What would invalidate this read
Operating margin currently stands at -35.84%. A decisive move in revenue — currently down 10.36% — would be the clearest signal to resolve the ambiguity.
Company profile
RxSight, Inc., a medical technology company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally.
CEORonald Kurtz
SectorHealthcare
IndustryMedical - Devices
Employees498
IPO dateJul 30, 2021
Valuation
Forward P/E—
EV/EBITDA-10.60
Enterprise value$420.14M
Stock splits
No stock splits recorded for this ticker.
Profitability & growth
Revenue growth-18.92%
Gross margin76.6%▲8.33%vs FY2024
Operating margin-35.84%▼36.04%vs FY2024
ROE-14.13%▼44.70%vs FY2024
Analyst consensus
RatingHold
Target price$10.75▲45.66%
3
Buy
7
Hold
2
Sell
Analyst ratings tend to be lagging indicators. Use as one signal among many.
Earnings
Full quarter-by-quarter history of actuals vs estimates. Switch into compare mode to inspect one metric year-over-year.
Next report
May 6, 2026
Q2 FY26 · EPS est -$0.12 · Revenue est $29.75M
View